Zymergen

Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Washington, D.C.--(Newsfile Corp. - September 13, 2024) - The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline.

SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects

Ginkgo Bioworks Holdings

BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen.

Ginkgo Bioworks Completes Acquisition of Zymergen

The stock price of Zymergen (ZY) fell by 4.65% in the most recent trading session. This is why.

Zymergen (ZY) Stock: Why It Fell 4.65%

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (NasdaqGS: ZY) to Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). Under the terms of the proposed transaction, shareholders of Zymergen will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each share of Zymergen that they own. KSF is seeking to determine whether this consideration and the

ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY

Hanger Inc

Infrastructure & Energy Alternatives

Silverback Therapeutics

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc. (NYSE: HNGR)'s  sale to Patient Square Capital for $18.75 in cash per share. If you are a Hanger shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY

Gemini Therapeutics

CarLotz

ManTech

NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gemini Therapeutics, Inc. (NASDAQ: GMTX)'s merger with Disc Medicine, Inc. Pre-merger Gemini shareholders are expected to own approximately 28% of the combined company. If you are a Gemini shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ

NEW YORK , July 27, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Zymergen Inc. (ZY), relating to its proposed acquisition by Ginkgo Bioworks Holdings, Inc. Under the terms of the agreement, ZY shareholders are expected to receive 0.9179 shares of Ginkgo common stock per share they own. Click here for more information: https://www.monteverdelaw.com/case/zymergen-inc.

Investor Alert - The M&A Class Action Firm Announces the Investigation of Zymergen Inc. - ZY

NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Infrastructure & Energy Alternatives, Inc. (NASDAQ: IEA)'s sale to MasTec for $10.50 per share in cash and 0.0483 of a MasTec share for each IEA share. If you are an IEA shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IEA, ZY, FLAC

NEW YORK , July 25, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. ("Zymergen" or the "Company") (NASDAQ: ZY), connected with the proposed acquisition of the Company by Ginkgo Bioworks Holdings, Inc. ("Ginkgo") (NYSE: DNA). Under the terms of the merger agreement, the Company's shareholders will receive 0.9179 shares of Ginkgo common stock for each Zymergen share owned, representing implied per-share merger consideration of approximately $2.68 based upon Ginkgo's July 22, 2022 closing price of $2.92.

SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.

Zymergen shares are rallying after an all-stock buyout from Ginkgo Bioworks. Cathie Wood's Ark owns both DNA shares and ZY stock.

Cathie Wood Loaded Up on Zymergen (ZY) Stock Before Ginkgo Buyout

Ginkgo Bioworks (DNA) announced it entered into a definitive agreement under which Ginkgo will acquire Zymergen. These are the details.

Why Ginkgo Bioworks (DNA) Is Buying Zymergen For $300 Million

Zymergen finally received some much-needed good news when Ginkgo Bioworks agreed to buy out the firm, sending ZY stock soaring. The post Zymergen (ZY) Stock Soars 20% on Acquisition News appeared first on InvestorPlace.

Zymergen (ZY) Stock Soars 20% on Acquisition News

MILWAUKEE , July 25, 2022 /PRNewswire/ -- Ademi LLP is investigating Zymergen (NASDAQ: ZY) for possible breaches of fiduciary duty and other violations of law in its transaction with Ginkgo.  Click here to learn how to join the action: https://www.ademilaw.com/case/zymergen-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Zymergen Inc. has obtained a Fair Price in its transaction with Ginkgo

The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.

Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Zymergen Inc. (NASDAQ: ZY) to Ginkgo Bioworks for 0.9179 Ginkgo shares for each Zymergen share is fair to Zymergen shareholders. Halper Sadeh encourages Zymergen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether

ZY Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Zymergen Inc. Is Fair to Shareholders

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end markets Zymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the acquisition Ginkgo's platform serves customers across industries as an enabling platform and Ginkgo will support Zymergen's plans to evaluate strategic alternatives for their Advanced Materials and Drug Discovery businesses Zymergen stockholders will own 5.25% of the pro forma combined company following the transaction BOSTON and EMERYVILLE, Calif. , July 25, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and the biotechnology company Zymergen (Nasdaq: ZY) announced they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.

Ginkgo to Acquire Zymergen

Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug discovery platform Octant doubles its initial investment in Zymergen's Automation Technology to significantly increase the scale and throughput of its drug discovery platform

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

EMERYVILLE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced an R&D supply agreement to provide Zymergen Z2TM polyimide powder to 3D4Makers for use in high performance 3D printing applications. 3D4Makers will convert the powder to filament, offering its first-ever polyimide filament to customers for use across a wide range of applications including aerospace, automotive, and transportation.

Zymergen Announces R&D Supply Agreement with 3D4Makers to Provide New Polyimide for Use in High-Performance 3D Printing Applications

Archer Aviation

Dare Bioscience

Check these penny stocks out for your watchlist right now The post Good Penny Stocks to Buy Now? 3 to Watch in June  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Good Penny Stocks to Buy Now? 3 to Watch in June

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation system to scale Octant's next-generation platform to develop breakthrough medicines.

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform

The stock for Zymergen Inc. has been in freefall since an initial recovery attempt following last year's disaster. The company will run out of cash in 2023 and prospects for viability remain murky.

Zymergen: A Humbled Company With A Business On The Ropes

Zymergen, Inc. (NASDAQ:ZY ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Carrie Mendivil - IR Jay Flatley - Acting CEO Ena Singh - CFO Conference Call Participants Matt Sykes - Goldman Sachs Steven Mah - Cowen Matt Larew - William Blair Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to the Zymergen First Quarter 2022 Financial Results Call.

Zymergen, Inc. (ZY) CEO Jay Flatley on Q1 2022 Results - Earnings Call Transcript

Zymergen (ZY) delivered earnings and revenue surprises of 1.41% and 57.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymergen (ZY) Reports Q1 Loss, Tops Revenue Estimates

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31, 2022.

Zymergen Reports Preliminary First Quarter 2022 Financial Results

Zymergen (ZY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Zymergen Stock (ZY)